Table 1.

Baseline characteristics and objective response.

Discovery cohortValidation cohort
Patient characteristicsn = 40n = 86
Age, years
 Median6769
 Range51–8431–85
Sex, n (%)
 Male26 (65.0)67 (77.9)
 Female14 (35.0)19 (22.1)
Histology, n (%)
 Squamous10 (25.0)24 (27.9)
 Nonsquamous30 (75.0)62 (72.1)
Smoking history, n (%)
 Current or former smoker29 (72.5)68 (79.1)
 Never smoked11 (27.5)18 (20.9)
Disease stage, n (%)
 c-stage III9 (22.5)18 (20.9)
 c-stage IV22 (55.0)55 (64.0)
 Postoperative recurrence9 (22.5)13 (15.1)
Driver mutation status, n (%)
 Wild type33 (82.5)73 (84.9)
 EGFR (19 del or L858R)7 (17.5)12 (14.0)
 ALK0 (0)1 (1.1)
Objective response at 9 weeks, n (%)
 CR or PR11 (27.5)12 (14.0)
 SD15 (37.5)31 (36.0)
 PD14 (35.0)43 (50.0)
  • Abbreviations: ALK, anaplastic lymphoma kinase; CR, complete response; c-stage, clinical stage; del, deletion.